Determination of the 'reflex range' and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system

Urology

Volumn 49, Issue 1, 1997, Pages 19-27

  Vashi, Apoorva R ^b   Wojno, Kirk J ^b   Henricks, Walter ^b   England, Barry A ^b   Vessella, Robert L ^b   Lange, Paul H ^b   Wright Jr , George L ^b   Schellhammer, Paul F ^b   Weigand, Ray A ^b   Olson, Robert M ^b   Dowell, Barry L ^b   Borden, Kimberlee K ^b   Oesterling, Joseph E ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR BIOPSY;

EID: 0031020862     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00511-0     Document Type: Article

References (37)

1. Parker SL, Tong T, Bolden S, and Wingo PA: Cancer statistics, 1996. CA Cancer J Clin 46: 5-29, 1996.
2. Wang MC, Valenzuela LA, Murphy GP, and Chu TM: Purification of a human prostate specific antigen. Invest Urol 17: 159-163, 1979.
3. Oesterling JE: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145: 907-923, 1991.
4. Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessela RL, and Lange PH: Screening for prostatic carcinoma with prostate specific antigen. J Urol 147: 841-845, 1992.
5. Catalona WJ, Richie JP, Ahmann FR: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J Urol 151: 1283-1290, 1994.
6. Catalona WJ, Smith DS, Ratliff TL, and Basler JW: Detection of organ confined cancer is increased through prostate specific antigen based screening. JAMA 270: 948-954, 1993.
7. Smith DS, and Catalona WJ: The nature of prostate cancer detected through prostate specific antigen based screening. J Urol 152: 1732-1736, 1994.
8. Epstein JI, Walsh PC, Carmichael M, and Brendler CB: Pathologic and clinical findings to predict tumor extent of nonpalpable (T1c) prostate cancer. JAMA 271: 368-374, 1994.
9. Stormont TJ, Farrow GM, Myers RP, Blute ML, Zincke H, Wilson TM, and Oesterling JE: Clinical stage BO or Tie prostate cancer: non-palpable disease identified by an elevated serum prostate specific antigen concentration. Urology 41: 3-8, 1993.
10. Benson MC, Whang IS, Olsson CA, McMahon DJ, and Cooner WH: The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 147: 817-821, 1992.
11. Seaman E, Whang IS, Olsson CA, Katz A, Cooner WH, and Benson MC: PSA density (PSAD). Role in patient evaluation and management. Urol Clin North Am 20: 653-664, 1993.
12. Oesterling JE, Chute CG, Jacobsen SJ, Guess HA, Panser LA, Johnson CL, and Lieber MM: Longitudinal changes in serum PSA (PSA velocity) in community based cohort of men (abstract). J Urol 149: 412A, 1993.
13. Carter HB, Parson JD, Metter EJ, Brant LJ, Chan DW, Andres R, Fozard JL, and Walsh PC: Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA 267: 2215-2220, 1992.
14. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, and Lieber MM: Serum prostate specific antigen in a community based population of healthy men. Establishment of age-specific reference ranges. JAMA 270: 860-864, 1993.
15. Dalkin BL, Ahmann F, Southwick P, and Bottacini MR: Derivation of normal prostate specific antigen level by age (abstract). J Urol 149: 413A, 1993.
16. Collins GN, Lee RJ, McKelvie GB, Rogers AC, and Hehir M: Relationship between prostate specific antigen, prostate volume and age in the benign prostate. Br J Urol 71: 445-450, 1993.
17. Christensson A, Laurell CB, and Lilja H: Enzymatic activity of the prostate specific antigen and its reactions with extra-cellular serine protease inhibitors. Eur J Biochem 194: 755-763, 1990.
18. Lilja H, Christensson A, Dahlen U, Matikainen M, Nilson O, Petterson K, and Lovgren T: Prostate specific antigen in serum occurs predominantly in complex with α1-antichymotrypsin. Clin Chem 37: 1618-1625, 1991.
19. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, and Alfthan O: A complex between prostate specific antigen and α1-antichymotrypsin is the major form of prostate specific antigen in the serum of patients with prostate cancer: assay of the compllex improves clinical sensitivity for cancer. Cancer Res 51: 222-226, 1991.
20. McCormak RT, Rittenhouse HG, Finlay JA, Sokoloff RL, Wang TJ, Wolfert RL, Lilja H, and Oesterling JE: Molecular forms of prostate specific antigen and the human kallikrein gene family: a new era. Urology 45: 729-744, 1995.
21. Christensson A, Bjork T, Nilsson O, Dahlen U, Matikainen M, Cockett A, Abrahamsson P, and Lilja H: Serum prostate specific antigen complexed to α1-antichymotrypsin as an indicator of prostate cancer. J Urol 150: 100-105, 1993.
22. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, and Nadler RB: Evaluation of percentage of free serum prostate specific antigen to improve specificity of prostate cancer screening. JAMA 274: 1214-1220, 1995.
23. Luderer AA, Chen Y, Soriano TF, Kramp WJ, Carlson G, Cuny C, Sharp T, Smith W, Petteway J, Brawer MK, et al: Measurement of the proportion of free to total prostate specific antigen improves diagnostic performance of prostate specific antigen in the diagnostic gray zone of total prostate specific antigen. Urology 46: 187-194, 1995.
24. Jacobsen SJ, Lilja H, Klee GG, Wright GL, Pettersson K, and Oesterling JE: Comparability of the Tandem-R and IMx assays for the measurement of serum prostate-specific antigen. Urology 44: 512-518, 1994.
25. Henricks WH, Oesterling JE, England B, and Wojno KJ: Freeze/thaw stability of percent free PSA and prediction of extracapsular extension (abstract). J Urol 155(5): 425A, 1996.
26. Oesterling JE, Wojno KJ, England B, Vessela RL, Lange PH, Noteboom J, Wright GL, Schellhammer PF, Weigand RA, Olson RM, et al: A comparison of free to total PSA ratio to total PSA for distinguishing benign prostatic hyperplasia from prostate cancer using the Abbott AxSYM system (abstract). J Urol 155(suppl): 370A, 1996.
27. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, and Redwine E: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317: 909-916, 1987.
28. Monda JM, Barry MJ, and Oesterling JE: Prostate specific antigen cannot distinguish stage T1a prostate cancer from benign prostate hyperplasia. J Urol 15: 1291-1295, 1994.
29. Hudson MA, Bahnson RR, and Catalona WJ: Clinical use of prostate-specific antigen in patients with prostate cancer. J Urol 142: 1011-1017, 1989.
30. Lange PH, Ercole CJ, Lightner DJ, Fraley EE, and Vessella R: The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 141: 873-879, 1989.
31. Mettlin C, Littrup PJ, Kane RA, Murphy GP, Lee F, Chesley A, Badalament R, and Mostofi FK: Relative sensitivity and specificity of serum prostate-specific antigen levels compared with age-referenced PSA, PSA density, and PSA change. Cancer 74: 1615-1620, 1994.
32. Hanley JA, and Mcneil BJ: The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143: 29-36, 1982.
33. Labrie F, Dupont A, Suburu R, Cusan L, Tremblay M, Gomez JL, and Emond J: Serum prostate-specific antigen as a pre-screening test for prostate cancer. J Urol 147: 846-852, 1992.
34. Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, Weber JP, and Walsh PC: Prostate-specific antigen in the staging of localized prostatic cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 143: 747-752, 1990.
35. Keetch DW, Catalona WJ, and Smith DS: Serial prostatic biopsies in men with persistently elevated serum prostate-specific antigen values. J Urol 151: 1571-1574, 1994.
36. Oesterling JE, Jacobsen SJ, Klee GG, Pettersson K, Piironen T, Abrahamsson PA, Stenman UH, Dowell B, Lovgren T, and Lilja H: Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 154: 1090-1095, 1995.
37. Yemoto CM, Nolley R, and Prestigiacomo AF: Free and total PSA density in patients with prostate cancer (CaP) and benign prostate hyperplasia (BPH) (abstract). J Urol 155: 374A, 1996.